GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AveXis Inc (NAS:AVXS) » Definitions » ROC (Joel Greenblatt) %

AveXis (AveXis) ROC (Joel Greenblatt) % : -1,495.03% (As of Mar. 2018)


View and export this data going back to 2016. Start your Free Trial

What is AveXis ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. AveXis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2018 was -1,495.03%.

The historical rank and industry rank for AveXis's ROC (Joel Greenblatt) % or its related term are showing as below:

AVXS's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -339.53
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

AveXis's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


AveXis ROC (Joel Greenblatt) % Historical Data

The historical data trend for AveXis's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AveXis ROC (Joel Greenblatt) % Chart

AveXis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
ROC (Joel Greenblatt) %
-109,850.00 -102,800.00 -29,221.97 -682.69 -548.35

AveXis Quarterly Data
Dec13 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -414.15 -631.12 -457.32 -644.04 -1,495.03

Competitive Comparison of AveXis's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, AveXis's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AveXis's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AveXis's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where AveXis's ROC (Joel Greenblatt) % falls into.



AveXis ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 8.321) - (48.724 + 0 + 9.589)
=-49.992

Working Capital(Q: Mar. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 11.636) - (68.414 + 0 + 4.413)
=-61.191

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of AveXis for the quarter that ended in Mar. 2018 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2017  Q: Mar. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-889.824/( ( (56.174 + max(-49.992, 0)) + (62.864 + max(-61.191, 0)) )/ 2 )
=-889.824/( ( 56.174 + 62.864 )/ 2 )
=-889.824/59.519
=-1,495.03 %

Note: The EBIT data used here is four times the quarterly (Mar. 2018) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AveXis  (NAS:AVXS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


AveXis ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of AveXis's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


AveXis (AveXis) Business Description

Traded in Other Exchanges
N/A
Address
AveXis Inc is a United States-based clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate in Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. AVXS-101 is designed to deliver a fully functional human survival motor neuron gene into the nuclei of motor neurons that then generates an increase in survival motor neuron protein levels. The company believes this will result in improved motor neuron function and patient outcomes.
Executives
Sean P. Nolan director, officer: President & CEO C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Session R.a. Ii officer: Sr. VP, Corp Strategy C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Paul B Manning director, other: Former 10% Owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Sukumar Nagendran officer: Sr. VP & Chief Medical Officer C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Frank Verwiel director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
James J Litalien officer: SrVP/Chief Reg&Quality Officer C/O SOMAXON PHARMACEUTICALS, INC., 3721 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO CA 92130
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Rick Modi officer: Chief Business Officer C/O AVEXIS INC, 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Phillip B. Donenberg officer: Chief Financial Officer C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Joao Md Siffert director 20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Bong Y Koh director 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn director, 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017